FDA Approves Gene Therapy for Spinal Muscular Atrophy
FDA Approves Gene Therapy for Spinal Muscular Atrophy
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
FDA Approves Gene Therapy for Spinal Muscular Atrophy
FDA Approves Gene Therapy for Spinal Muscular Atrophy

At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.

At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.

spinal muscular atrophy

Sorry, no results found.

We tried our best, but we couldn't find any articles relating to .